Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	196.55	319.74	56.86	67.21
Short-Term Investments	115.83	31.02	-	-
Cash & Short-Term Investments	312.38	350.77	56.86	67.21
Cash Growth	740.77%	516.93%	-15.40%	-
Prepaid Expenses	3.73	3.07	1.65	1.24
Restricted Cash	-	0.09	-	-
Other Current Assets	-	2	1.3	-
Total Current Assets	317.81	355.92	59.8	68.44
Property, Plant & Equipment	1.28	1.19	1.01	1.8
Long-Term Deferred Charges	-	-	1.39	-
Other Long-Term Assets	12.85	12.86	5.97	4.33
Total Assets	333.77	369.97	68.18	74.58
Accounts Payable	20.02	17.14	5.4	5.82
Accrued Expenses	28.2	39.16	17.01	19.44
Current Portion of Leases	0.91	0.79	0.56	0.72
Current Income Taxes Payable	0.01	0.21	0.3	-
Total Current Liabilities	49.13	57.29	23.26	25.97
Long-Term Debt	-	-	20.3	-
Long-Term Leases	0.32	0.22	0.26	0.81
Total Liabilities	49.45	57.51	43.82	26.78
Common Stock	0	0	-	0
Additional Paid-In Capital	705.14	699.65	4.65	1.03
Retained Earnings	-420.96	-387.39	-230.4	-193.28
Comprehensive Income & Other	0.14	0.19	0.04	-0.04
Total Common Equity	284.32	312.46	-225.72	-192.29
Shareholders' Equity	284.32	312.46	24.37	47.8
Total Liabilities & Equity	333.77	369.97	68.18	74.58
Total Debt	1.23	1	21.11	1.53
Net Cash (Debt)	311.15	349.76	35.74	65.68
Net Cash Growth	1906.02%	878.52%	-45.58%	-
Net Cash Per Share	13.38	26.50	23.34	44.02
Filing Date Shares Outstanding	41.83	41.8	1.58	1.55
Total Common Shares Outstanding	41.82	41.79	1.58	1.55
Working Capital	268.68	298.63	36.55	42.48
Book Value Per Share	6.80	7.48	-143.15	-124.11
Tangible Book Value	284.32	312.46	-225.72	-192.29
Tangible Book Value Per Share	6.80	7.48	-143.15	-124.11

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q